IL-35 (human):Fc (human) (rec.)

CHF 320.00
In stock
CHI-HF-21035-C02525 µgCHF 320.00
 
More Information
Product Details
Synonyms Interleukin-35
Product Type Protein
Properties
Source/Host CHO cells
Sequence The human IL-35 complex composed of the Ebi3 subunit (aa 21-229) and the IL-12a (p35) subunit (aa 57-253) is fused through a polypeptide linker to the Fc portion of human IgG1.
Crossreactivity Human
Biological Activity Bioactivity was measured in a cell proliferation assay using anti-CD3 activated human peripheral mononuclear cells.
Purity ≥98% (SDS-PAGE)
Endotoxin Content <0.06EU/μg protein (LAL test; Lonza).
Reconstitution Reconstitute at 100μg/ml in sterile PBS.
Formulation Lyophilized from 0.2μm-filtered solution in PBS.
Other Product Data NCBI reference NP_005746.2: Ebi3 subunit (human)
NCBI reference NP_000873.2: IL-12a subunit (human)
Declaration Manufactured by Chimerigen.
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs. Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells' ability to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy.
Product References
  1. EBI3 downregulation contributes to type I collagen overexpression in scleroderma skin: H. Kudo, et al.; J. Immunol. 195, 3565 (2015)
  2. A potential immunopathogenic role for reduced IL-35 expression in allergic asthma: W. Wang, et al.; J. Asthma 52, 763 (2015)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.